undamentalytics Newsletter
Sign in

Rigel Pharmaceuticals Inc (RIGL) stock

Add to watchlist

Add holding +

NASDAQ: RIGL Nasdaq Pharmaceuticals Next results ~November 5, 2026

Rigel Pharmaceuticals Inc is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Rigel Pharmaceuticals Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 3 sales by directors and officers, last 12 monthsInsider trades
  • Funds82 adding, 81 cuttingOf 37 active managers that changed their stake, 15 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Rigel Pharmaceuticals files

Where Rigel Pharmaceuticals stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $277m, up 3.3% on a year earlier, slower than the 47.6% growth a quarter earlier. Free-cash-flow margin rose to 28.7% from 24.6% a year earlier. Operating margin narrowed to 31.5% from 39.0%. The diluted share count is up 8.7% on a year earlier, which dilutes existing holders. It passes 3 of our 3 financial-health checks.

Our model value for Rigel Pharmaceuticals is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 4, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Rigel Pharmaceuticals Inc's trailing-twelve-month revenue grew 3.3% year on year, with a free-cash-flow margin of 28.7%.

Our discounted-cash-flow model values the business at ~$81 per share in the base case (~$62–$100 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 20.6% while net income grew 229.1%: a 208pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • High operating margin. 31.5% of revenue is left as operating profit.
  • Strong cash generation. 28.7% of revenue turned into free cash flow.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Growth slowing. The growth rate is 44.3 points lower than a quarter earlier.
  • Margins narrowing. Operating margin is down 7.6 points on a year ago.
  • Share dilution. Diluted shares rose 8.7% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 62% and a beta of 0.9 against the S&P 500.
  • Weak cash conversion. Free cash flow was 25% of net income over the last 12 months.
  • Heavily shorted. 15.0% of the shares available to trade are sold short (11.4 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 4, 2026
Earnings per share
$0.88 against an average estimate of -$0.08: beat by 1266.8%
Revenue
$79m, down 22.6% on a year earlier
Share reaction
+8.1% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 5, 2026; average EPS estimate $0.96

Rigel Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.5%
  • 1 week+1.2%
  • 1 month+7.2%
  • This year+18.0%
  • 1 year+60.0%
  • 5 years+45.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$277M
Operating margin
31.5%
Net margin
116.3%
EPS (TTM, diluted)
$16.45

Growth

Revenue growth
+3.3%
Change in growth rate
−44.3 pts
Share count change
+8.7%

Cash

Free cash flow (TTM)
$79.4M
FCF margin
28.7%
Stock pay % of revenue
5.9%

Earnings

Last results
August 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Rigel Pharmaceuticals Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Rigel Pharmaceuticals Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.09 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$44 ~$45–$91 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Rigel Pharmaceuticals Inc with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$23.80$38.80$23.00$21.40$35.00$26.50$15.00$14.50$16.82$42.83$50.53
Market value$225m$490m$369m$358m$591m$452m$256m$252m$297m$807m$989m
+ Net debt (− = net cash)−$18m−$38m−$76m−$13m−$10m$1m$16m$27m$3m$12m−$21m
Enterprise value$207m$452m$293m$346m$580m$453m$271m$280m$301m$819m$968m
Multiples
Price / sales 11.0x109.3x8.3x6.0x5.4x3.0x2.1x2.2x1.7x2.7x3.6x
Price / earnings ————————17.0x2.2x3.1x
Price / free cash flow —————86.0x——9.5x10.7x12.5x
EV / EBITDA ————————11.4x6.4x10.8x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

29 /100

Weak moat

How hard Rigel Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 6 / 20

    Cash operating profit has been a median 5.7% of total assets over 8 years.

  • Pricing power 12 / 20

    Gross margin has been a median 92.0%, moving by 21.1 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -15.4%; its worst year was -93.6%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 2 of 8 years, at a median -17.9% of revenue.

  • Discipline 4 / 20

    The diluted share count rose 17.1% over five years; stock-based pay has been a median 7.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (34 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $80m and EPS of $0.96 (range $0.77 to $1.07) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $3.54 −45% $306m +4%
Next $4.94 +39% $373m +22%

Next year's EPS estimate has moved +2.2% in 90 days, across 4 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +22.5% on 90 days ago. In the last 30 days, 1 analyst raised Rigel Pharmaceuticals Inc's forecast and 3 cut it.

Consensus EPS forecast Rigel Pharmaceuticals Inc, last 90 days
$2.00 $3.00 $4.00 $5.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $2.89 Current fiscal year, 60 days ago: $3.54 Current fiscal year, 30 days ago: $3.54 Current fiscal year, 7 days ago: $3.54 Current fiscal year, Now: $3.54 $3.54 Next fiscal year, 90 days ago: $4.83 Next fiscal year, 60 days ago: $4.94 Next fiscal year, 30 days ago: $4.94 Next fiscal year, 7 days ago: $4.94 Next fiscal year, Now: $4.94 $4.94

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $2.89$4.83
60 days ago $3.54$4.94
30 days ago $3.54$4.94
7 days ago $3.54$4.94
Now $3.54$4.94

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.08 $0.88 +1266.8%
Mar 2026 $0.87 $0.44 −49.5%
Dec 2025 $1.20 $1.12 −6.8%
Sept 2025 $0.94 $1.46 +56.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy360%
Hold240%
Sell00%

Monthly trend

  1. Oct 2026325
  2. Sep 2026325
  3. Aug 2026325
  4. Jul 2026325

Counts of recommendations published by analysts covering Rigel Pharmaceuticals Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
15.0%
of tradable shares
Days to cover
11.44
at average volume
Short interest, 1 month
−14%
to October 15, 2026
Held by institutions
92%
of shares
Held by insiders
3.4%
of shares
Employees
172
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +60.0%

$31.58 on October 31, 2025 to $50.53

ThenNowEffect
Revenue (last 12 months) $268m $277m +3.3%
Net margin 36.5% 116.3% +218.5%
P/E multiple 5.8x 3.1x −47.1%
Share count 18m 20m −8.0%

Biggest factor: net margin.

Last 3 years +474.2%

$8.80 on November 3, 2023 to $50.53

ThenNowEffect
Revenue (last 12 months) $127m $277m +118.6%
P/S multiple 1.2x 3.6x +197.2%
Share count 17m 20m −11.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
RIGL−24%−43%−3%+16%+155%+18%
Industry peers (median)−18%−52%−14%−2%+7%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
RIGL33%33%42%42%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
RIGL−52%−81%−64%−51%−36%−46%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 86% from February 8, 2021 to June 10, 2022. Getting back needed a 636% gain, reached on November 24, 2025, 1263 days after the low.

Price behaviour

52-week range
$25.44 – $51.45
From 52-week high
−1.8%
vs 50-day average
+5.7%
vs 200-day average
+35.8%
Volatility (1 year)
63%
Beta vs S&P 500
0.89

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±15.6%
After a week
6 up, 6 down
typical move ±26.5%
After a month
8 up, 4 down
typical move ±32.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +8.1% +1.6% +12.3% +32.0%
May 5, 2026 −9.7% +2.2% −0.6% +2.4%
March 3, 2026 −14.4% −0.2% −17.9% −20.6%
January 12, 2026 −7.1% 0.0% −11.0% −14.4%
November 4, 2025 +23.5% −0.8% +23.8% +54.6%
August 5, 2025 +31.5% +0.3% +52.3% +77.0%
May 6, 2025 −3.3% −0.4% −4.3% +9.7%
March 4, 2025 −9.3% −0.1% −12.9% −18.6%
January 13, 2025 +2.7% +0.3% +34.2% +28.1%
November 7, 2024 +46.4% +1.2% +82.1% +53.6%
August 6, 2024 +12.2% +0.2% +44.0% +52.4%
May 7, 2024 −18.9% +0.1% −22.1% −21.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Rigel Pharmaceuticals Inc
$100M $150M $200M $250M $300M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $132.4M Revenue (TTM), FY23 Q4: $116.9M Revenue (TTM), FY24 Q1: $120.3M Revenue (TTM), FY24 Q2: $130.3M Revenue (TTM), FY24 Q3: $157.5M Revenue (TTM), FY24 Q4: $179.3M Revenue (TTM), FY25 Q1: $203.1M Revenue (TTM), FY25 Q2: $267.9M Revenue (TTM), FY25 Q3: $282.1M Revenue (TTM), FY25 Q4: $294.3M Revenue (TTM), FY26 Q1: $299.8M Revenue (TTM), FY26 Q2: $276.8M $276.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $132.4M
FY23 Q4 $116.9M
FY24 Q1 $120.3M
FY24 Q2 $130.3M
FY24 Q3 $157.5M
FY24 Q4 $179.3M
FY25 Q1 $203.1M
FY25 Q2 $267.9M
FY25 Q3 $282.1M
FY25 Q4 $294.3M
FY26 Q1 $299.8M
FY26 Q2 $276.8M
Revenue growth, TTM YoY Rigel Pharmaceuticals Inc
-50% 0% 50% 100% 150% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 48.1% Revenue growth, TTM YoY, FY23 Q4: -2.8% Revenue growth, TTM YoY, FY24 Q1: -7.1% Revenue growth, TTM YoY, FY24 Q2: 2.9% Revenue growth, TTM YoY, FY24 Q3: 19.0% Revenue growth, TTM YoY, FY24 Q4: 53.4% Revenue growth, TTM YoY, FY25 Q1: 68.7% Revenue growth, TTM YoY, FY25 Q2: 105.6% Revenue growth, TTM YoY, FY25 Q3: 79.1% Revenue growth, TTM YoY, FY25 Q4: 64.1% Revenue growth, TTM YoY, FY26 Q1: 47.6% Revenue growth, TTM YoY, FY26 Q2: 3.3% 3.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 48.1%
FY23 Q4 -2.8%
FY24 Q1 -7.1%
FY24 Q2 2.9%
FY24 Q3 19.0%
FY24 Q4 53.4%
FY25 Q1 68.7%
FY25 Q2 105.6%
FY25 Q3 79.1%
FY25 Q4 64.1%
FY26 Q1 47.6%
FY26 Q2 3.3%
Operating margin (TTM) Rigel Pharmaceuticals Inc
-20% 0% 20% 40% 60% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -15.4% Operating margin (TTM), FY23 Q4: -17.5% Operating margin (TTM), FY24 Q1: -12.2% Operating margin (TTM), FY24 Q2: -6.9% Operating margin (TTM), FY24 Q3: 6.0% Operating margin (TTM), FY24 Q4: 13.5% Operating margin (TTM), FY25 Q1: 21.6% Operating margin (TTM), FY25 Q2: 39.0% Operating margin (TTM), FY25 Q3: 42.2% Operating margin (TTM), FY25 Q4: 42.6% Operating margin (TTM), FY26 Q1: 41.6% Operating margin (TTM), FY26 Q2: 31.5% 31.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -15.4%
FY23 Q4 -17.5%
FY24 Q1 -12.2%
FY24 Q2 -6.9%
FY24 Q3 6.0%
FY24 Q4 13.5%
FY25 Q1 21.6%
FY25 Q2 39.0%
FY25 Q3 42.2%
FY25 Q4 42.6%
FY26 Q1 41.6%
FY26 Q2 31.5%
FCF margin (TTM) Rigel Pharmaceuticals Inc
-20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -16.2% FCF margin (TTM), FY23 Q4: -4.9% FCF margin (TTM), FY24 Q1: -5.6% FCF margin (TTM), FY24 Q2: -9.4% FCF margin (TTM), FY24 Q3: 6.8% FCF margin (TTM), FY24 Q4: 17.6% FCF margin (TTM), FY25 Q1: 17.5% FCF margin (TTM), FY25 Q2: 24.6% FCF margin (TTM), FY25 Q3: 24.2% FCF margin (TTM), FY25 Q4: 25.7% FCF margin (TTM), FY26 Q1: 26.4% FCF margin (TTM), FY26 Q2: 28.7% 28.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -16.2%
FY23 Q4 -4.9%
FY24 Q1 -5.6%
FY24 Q2 -9.4%
FY24 Q3 6.8%
FY24 Q4 17.6%
FY25 Q1 17.5%
FY25 Q2 24.6%
FY25 Q3 24.2%
FY25 Q4 25.7%
FY26 Q1 26.4%
FY26 Q2 28.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 20 4 45 59 109 149 120 117 179 294 277
Gross profit — — 44 58 108 148 118 110 161 275 253
EBITDA −69 −79 −72 −68 −28 −11 −55 −19 26 128 90
Operating income −70 −80 −73 −69 −29 −12 −56 −20 24 125 87
Net income −69 −78 −70 −67 −30 −18 −59 −25 17 367 322
Diluted EPS −$7.30 −$6.20 −$4.40 −$4.00 −$1.80 −$1.10 −$3.44 −$1.44 $0.99 $19.48 $16.45
Growth (year on year)
Revenue — −78.0% +892.6% +33.2% +83.2% +37.4% −19.4% −2.8% +53.4% +64.1% +3.3%
EBITDA — — — — — — — — — +384.0% −16.2%
Operating income — — — — — — — — — +418.6% −16.8%
Net income — — — — — — — — — +>999% +229.1%
Diluted EPS — — — — — — — — — +>999% +202.7%
Margins
Gross margin — — 99.4% 98.5% 99.2% 99.3% 98.5% 93.9% 89.6% 93.3% 91.4%
EBITDA margin −337.5% <−999% −162.0% −115.4% −26.0% −7.6% −45.4% −16.5% 14.7% 43.5% 32.4%
Operating margin −342.2% <−999% −163.3% −116.5% −26.7% −8.4% −46.2% −17.5% 13.5% 42.6% 31.5%
Net margin −339.6% <−999% −158.3% −112.8% −27.4% −12.0% −48.7% −21.5% 9.8% 124.7% 116.3%
Free-cash-flow margin −376.3% <−999% −134.7% −72.5% −49.2% 3.5% −61.7% −4.9% 17.6% 25.7% 28.7%
Cash flow
Cash from operations −76 −78 −59 −42 −52 6 −74 −6 31 76 79
Capital spending 1 0 1 1 1 1 0 0 0 0 0
Free cash flow −77 −78 −60 −43 −53 5 −74 −6 31 76 79
Stock-based pay 7 6 8 9 7 9 12 9 12 13 16
Free cash flow after stock pay −84 −84 −68 −52 −61 −4 −87 −15 19 63 63
Balance sheet
Cash 18 38 76 23 30 19 24 33 57 41 61
Total debt 0 0 0 10 20 20 40 60 60 53 40
Net debt (negative = net cash) −18 −38 −76 −13 −10 1 16 27 3 12 −21
Diluted shares 9m 13m 16m 17m 17m 17m 17m 17m 18m 19m 20m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 3 checks passed · June 30, 2026
What it owns · $521m
Short-term assets $186mLonger-term assets $336m
What it owes, and who funded it · $521m
Short-term liabilities $96mLonger-term liabilities $0mShareholders' equity $425m
  • Short-term assets cover short-term liabilities $186m of assets due within a year against $96m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $186m short-term assets against $58,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of $87m against $6m of interest.

From Rigel Pharmaceuticals Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+8.7%
year over year
R&D spending
15.8%
of revenue
Sales & admin spending
44.2%
of revenue
Days sales outstanding
74 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated RIGL HROW EOLS ACB VNDA XERS Median
Revenue, last 12 months $277m $276m $316m $232m $229m $335m $276m
Revenue growth, last 12 months 3.3% 21.1% 13.9% 11.7% 8.1% 36.3% 9.7%
Revenue growth, 3-year average 29.8% 39.0% 23.4% — 2.7% 35.8% 5.9%
Revenue growth, latest quarter −22.6% 10.9% 21.2% — 24.1% 28.7% 6.4%
Gross margin 91.4% 73.3% 66.7% 42.6% 90.0% — 63.8%
Operating margin 31.5% −1.0% −5.9% 1.9% −77.6% 10.9% −5.9%
Operating margin, 3-year average 21.2% −0.1% −12.6% — −51.4% −4.5% −6.4%
Net margin 116.3% −13.5% −10.8% −42.4% −119.9% −5.1% −7.0%
Cash from operations / revenue 28.7% 2.3% −4.9% −4.2% −60.7% 16.9% 10.8%
Free-cash-flow margin 28.7% 1.8% −5.8% −5.4% −61.0% 16.5% 9.3%
Free-cash-flow margin, 3-year average 14.6% 0.8% −9.6% — −36.6% −4.1% 7.4%
Stock pay / revenue 5.9% 5.3% 6.6% 2.3% 4.1% 8.4% 3.7%
Change in share count 8.7% 0.5% 2.3% 3.0% 1.8% 19.6% 2.0%

Median of all 76 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Gross Product $310M ▲ 47.7%
Products $232M ▲ 60.1%
Contract Revenues From Collaborations $62M ▲ 80.5%
Release of Share Cost Liability $40M —
Royalty Delivery of Drug Supplies and Others $19.1M ▼ 6.5%
Development Milestones $3M —
Government Contract $265,000 —
Licenses $0 ▼ 100.0%
Discounts and Allowances -$78M —

These categories overlap or exclude eliminations, so shares aren't shown.

From Rigel Pharmaceuticals Inc's 10-K filed March 3, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$640M
Institutions reporting
154
Shares held vs prior quarter
▲ 2.4%
Positions opened / closed
30 / 26

Top buyers and sellers, Q2 2026: 82 institutions bought and 81 sold ; the biggest buyer was Soleus Capital Management, L.P (+1.8M shares) and the biggest seller Qube Research & Technologies Ltd (−344K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $75.9M 1.9M 11.8% ▲ 9.7%
Soleus Capital Management, L.P. $72.1M 1.8M 11.3% ▲ 18335.0%
Armistice Capital, LLC $65.4M 1.7M 10.2% ▲ 30.6%
State Street Corp $40.7M 1.0M 6.4% ▼ 7.2%
Vanguard Capital Management LLC $30.7M 785K 4.8% ▲ 2.7%
American Century Companies Inc $29M 742K 4.5% ▲ 36.2%
LSV Asset Management $28.2M 722K 4.4% ▲ 20.0%
Acadian Asset Management LLC $23.1M 592K 3.6% ▼ 11.2%
D. E. Shaw & Co., Inc. $21.2M 543K 3.3% ▲ 21.7%
Geode Capital Management, LLC $18.9M 483K 3.0% ▲ 9.7%
Marshall Wace, LLP $14.4M 367K 2.2% ▼ 38.6%
Cm Management, LLC $9.8M 250K 1.5% ▲ 6.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Rigel Pharmaceuticals Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $305,865 3 trades by 2 insiders · 52% under pre-set plans
Net ▼ $305,865 net selling
Insider Date Trade Shares Price Value
Ali-Jackson Kamil Director June 22, 2026 Sell pre-set plan 2,500 $35.00 $87,500
Ali-Jackson Kamil Director May 26, 2026 Sell pre-set plan 2,500 $29.17 $72,925
Moos Walter H Director February 20, 2026 Sell 4,000 $36.36 $145,440

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 4, 2026
  • May 5, 2026
  • March 3, 2026
  • January 12, 2026
  • November 4, 2025
  • August 5, 2025

Recent SEC filings

Data status

When each part of this page on Rigel Pharmaceuticals Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Rigel Pharmaceuticals Inc in brief

What does Rigel Pharmaceuticals Inc do?
Rigel Pharmaceuticals Inc is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Rigel Pharmaceuticals Inc's stock ticker?
Rigel Pharmaceuticals Inc trades under the ticker RIGL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Rigel Pharmaceuticals Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Rigel Pharmaceuticals Inc reported revenue of $277M, 3.3% higher than a year earlier, according to its SEC filings.
What is Rigel Pharmaceuticals Inc's free cash flow?
Rigel Pharmaceuticals Inc's free-cash-flow margin is 28.7% of revenue over the trailing twelve months.
Who are Rigel Pharmaceuticals Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Soleus Capital Management, L.P. and Armistice Capital, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Rigel Pharmaceuticals Inc's market cap?
On November 2, 2026, Rigel Pharmaceuticals Inc's market capitalisation was about $989M, with a price-to-earnings ratio of 3.1 and net debt of -$20.8M. Market figures come from third-party market data and may be delayed.
Who are Rigel Pharmaceuticals Inc's competitors?
In our Pharmaceuticals peer group, the companies closest to Rigel Pharmaceuticals Inc are Harrow, Inc., Evolus, Inc., Aurora Cannabis Inc, Vanda Pharmaceuticals Inc. and Xeris Biopharma Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Rigel Pharmaceuticals Inc's.
Are insiders buying or selling Rigel Pharmaceuticals Inc stock?
Over the last 12 months, Rigel Pharmaceuticals Inc's directors and officers reported 0 open-market purchases and 3 sales on Form 4. The insider trading page charts every trade.
When is Rigel Pharmaceuticals Inc's next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Rigel Pharmaceuticals Inc announces its own schedule.